Understanding the mechanisms of action of antiangiogenic agents in metastatic colorectal cancer: a clinician's perspective.
Multiple clinical trials using bevacizumab, ziv-aflibercept, and regorafenib have recently demonstrated efficacy for patients with metastatic colorectal cancer. While the net clinical benefit of each of these therapies in the second-line and refractory disease setting appears to be similar, important distinctions exist between the agents at the pharmacodynamic, tumor microenvironment, and clinical levels. The purpose of this review is to survey the preclinical evidence regarding the mechanisms of action of these novel antiangiogenic agents and provide an overview of their respective clinical activity, while highlighting distinctions between therapies. Fundamental understanding of these distinctions may aid in clinical decisions and choice of antiangiogenic therapies.
['Clarke|J M|JM|', 'Hurwitz|H I|HI|', 'Rangwala|F|F|']
D020533:Angiogenesis Inhibitors D000818:Animals D061067:Antibodies, Monoclonal, Humanized D000068258:Bevacizumab D017326:Clinical Trials, Phase III as Topic D015179:Colorectal Neoplasms D004354:Drug Screening Assays, Antitumor D006801:Humans D010671:Phenylurea Compounds D011725:Pyridines D040262:Receptors, Vascular Endothelial Growth Factor D011993:Recombinant Fusion Proteins D059016:Tumor Microenvironment
Antiangiogenic Metastatic colorectal cancer Bevacizumab Ziv-aflibercept Regorafenib Angiogenesis Ramucirumab